|
|
| | BMS-P5 free base Basic information |
| Product Name: | BMS-P5 free base | | Synonyms: | BMS-P5;Methanone, [(2S,5R)-5-amino-2-methyl-1-piperidinyl][2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-benzimidazol-5-yl]-;BMS-P5 free base;BMS-P-5 free base,BMS P5 free base,myeloma,Inhibitor,inhibit,Protein Arginine Deiminase,BMS-P5,Multiple,NET,BMSP5 free base,Peptidylarginine Deiminase;((2S,5R)-5-Amino-2-methylpiperidin-1-yl)(2-(1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone;(2S,5R)-5-amino-2-methyl-1-piperidinyl][2-[1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-methanone;BMS-P5 free base, 10 mM in DMSO;BMS-P5 ，S9644 | | CAS: | 1550371-22-6 | | MF: | C27H32N6O2 | | MW: | 472.58 | | EINECS: | | | Product Categories: | | | Mol File: | 1550371-22-6.mol |  |
| | BMS-P5 free base Chemical Properties |
| Boiling point | 728.7±70.0 °C(Predicted) | | density | 1.40±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 20 mg/ml,DMSO: 5 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:8): 0.11 mg/ml | | form | A crystalline solid | | pka | 9.87±0.40(Predicted) | | color | White to off-white |
| | BMS-P5 free base Usage And Synthesis |
| Uses | BMS-P5 free base is a selective and orally active peptidylarginine deiminase 4 (PAD4) inhibitor with an IC50 of 98 nM. BMS-P5 free base shows selective for PAD4 over PAD1, PAD2, and PAD3. BMS-P5 free base blocks multiple myeloma (MM)-induced neutrophil extracellular trap (NET) formation and delays progression of MM in a syngeneic mouse model[1]. | | in vivo | BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice[1].
BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression[1].
| Animal Model: | Syngeneic mouse model of MM[1]. | | Dosage: | 50 mg/kg. | | Administration: | Oral gavage, twice a day beginning on day 3 after tumor cell injection. | | Result: | Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice. |
| | References | [1] Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19(7):1530-1538. DOI:10.1158/1535-7163.MCT-19-1020 |
| | BMS-P5 free base Preparation Products And Raw materials |
|